Harrow, Inc. (HROW) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024. Harrow, Inc. is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic products. The company operates a single reportable segment and owns ImprimisRx, a leading ophthalmology-focused compounding business.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $48.94 million | $33.47 million | $83.53 million | $59.57 million |
| Gross Profit | $36.40 million | $23.47 million | $60.43 million | $41.30 million |
| Gross Margin | 74.4% | 70.1% | 72.4% | 69.3% |
| Net Loss | $(6.47) million | $(4.23) million | $(20.04) million | $(10.87) million |
| Diluted EPS | $(0.18) | $(0.14) | $(0.56) | $(0.36) |
| Cash and Equivalents | $70.97 million (as of June 30, 2024) | |||
| Total Debt (Net) | $185.02 million (as of June 30, 2024) | |||
| Operating Cash Flow (YTD) | $(7.37) million used |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 46% year-over-year for the quarter and 40% year-over-year for the six months. This was driven primarily by increased sales volumes of branded ophthalmology products (e.g., IHEEZO, VEVYE) and the absence of "transfer of acquired product sales" revenue that occurred in 2023.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose significantly ($31.8M in Q2 2024 vs. $20.0M in Q2 2023) due to regulatory enhancements, integration of recent acquisitions, and headcount expansion to support the commercial launch of VEVYE. R&D expenses also increased ($3.1M vs. $1.2M) due to expanded portfolio activities.
- Investment Loss: The company recorded a loss of $3.17 million for the six months ended June 30, 2024, related to the sale of its entire investment in Eton Pharmaceuticals. This contrasts with a gain in the prior year period.
- Debt Obligations: Total notes payable (net) increased slightly to $185.0 million. The company carries significant interest expense, totaling $10.9 million for the six months ended June 30, 2024.
Outlook, Management Commentary, and Risks
- TRIESENCE Re-launch: The company successfully manufactured a Process Performance Qualification (PPQ) batch in June 2024 and a second in July 2024. A third batch is expected before the end of Q3 2024. Successful completion could allow a U.S. re-launch before year-end, triggering a $37 million milestone payment to Novartis.
- VEVYE Launch: Launched in January 2024 as the first water-free cyclosporine solution. The company is actively managing market access and reimbursement.
- IHEEZO Reimbursement: CMS confirmed IHEEZO is separately payable in physician offices and increased the Medically Unlikely Edit (MUE) from 1 to 2, effective July 1, 2024, supporting bilateral procedures.
- Liquidity: Management believes current cash ($71.0M) is sufficient for operations for at least the next 12 months. However, the company may need to seek additional financing for future acquisitions or if growth outpaces expectations.
- Risks: Key risks include regulatory restrictions on compounding, the ability to successfully re-launch TRIESENCE, high debt service costs, and concentration risk (one customer accounted for 45% of Q2 revenue).
Investor Verification Checklist
- Verify the status of the third TRIESENCE PPQ batch and the timeline for the $37 million milestone payment to Novartis.
- Monitor the impact of the increased IHEEZO MUE on Q3 and Q4 sales volumes.
- Review the trajectory of SG&A expenses to ensure they align with revenue growth and do not erode margins further.
- Assess the company's ability to service its ~$193 million gross debt load given the current operating cash burn.
- Confirm the valuation and potential exit strategy for the remaining investment in Melt Pharmaceuticals (carrying value is currently $0 due to equity method losses).